Search

Colorectal cancer (CRC) screening has been proven to reduce both mortality and the incidence of this disease. Most CRC screening programs are based on fecal immunochemical tests (FITs), which have a low participation rate. Searching for blood protein biomarkers can lead to the development of a more accepted screening test. The aim of this systematic review was to compare the diagnostic potential of the most promising serum protein biomarkers. A systematic review based on PRISMA guidelines was conducted in the PubMed and Web of Science databases between January 2010 and December 2023. Studies assessing blood protein biomarkers for CRC screening were included. The sensitivity, specificity, and area under the ROC curve of each biomarker were collected. Among 4685 screened studies, 94 were considered for analysis. Most of them were case–control studies, leading to an overestimation of the performance of candidate biomarkers. The performance of no protein biomarker or combination of biomarkers appears to match that of the FIT. Studies with a suitable design and population, testing new assay techniques, or based on algorithms combining FIT with serum tests are needed. [ABSTRACT FROM AUTHOR]

CONTRIBUTIONS OF MOLECULAR BIOLOGY TO THE MANAGEMENT OF COLORECTAL CANCER. Colorectal cancer (CRC) is a major public health problem affecting almost 43.000 people a year and causing 17.000 deaths. Advances in molecular biology have made it possible to identify some of the mechanisms involved in colorectal carcinogenesis and tumor proliferation. Some molecular alterations are now routinely investigated to adapt follow-up and therapeutic decisions in both localized and metastatic CRC., Competing Interests: A. Grancher déclare avoir participé à des interventions ponctuelles pour OncoDiag et avoir été pris en charge, à l’occasion de déplacements pour congrès, par Bayer et Roche.S. Cuissy déclare n’avoir aucun lien d’intérêts. D. Sefrioui déclare avoir participé à des interventions ponctuelles pour Ipsen, Roche, Bayer, Viatris, Servier, Pierre Fabre, Deciphera pharmaceuticals, et avoir été pris en charge, à l’occasion de déplacements pour congrès, par Servier, MSD, AstraZeneca, Ipsen, Roche. F. Di Fiore déclare avoir participé à des interventions ponctuelles pour Amgen, AstraZeneca, Bayer, BMS, Incyte, Ipsen, Merck, MSD, Pierre Fabre, Roche, Servier, Viatris.